Review article: causative factors and the clinical management of patients with Crohn’s disease who lose response to anti-TNF-α therapy
- 3 May 2011
- journal article
- review article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 34 (1), 1-10
- https://doi.org/10.1111/j.1365-2036.2011.04679.x
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn’s diseaseAlimentary Pharmacology & Therapeutics, 2010
- The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current managementJournal of Crohn's and Colitis, 2010
- Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A ReviewThe American Journal of Gastroenterology, 2009
- Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohortGut, 2008
- Maintenance Therapy with Certolizumab Pegol for Crohn's DiseaseNew England Journal of Medicine, 2007
- Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM TrialGastroenterology, 2007
- Infliximab for Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2005
- Infliximab Maintenance Therapy for Fistulizing Crohn's DiseaseNew England Journal of Medicine, 2004
- Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's DiseaseNew England Journal of Medicine, 2003
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002